KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Long-Term Investments: 2019-2025

Historic Long-Term Investments for Royalty Pharma (RPRX) over the last 6 years, with Sep 2025 value amounting to $302.5 million.

  • Royalty Pharma's Long-Term Investments fell 53.98% to $302.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $302.5 million, marking a year-over-year decrease of 53.98%. This contributed to the annual value of $693.5 million for FY2024, which is 58.66% up from last year.
  • Royalty Pharma's Long-Term Investments amounted to $302.5 million in Q3 2025, which was up 9.64% from $275.9 million recorded in Q2 2025.
  • In the past 5 years, Royalty Pharma's Long-Term Investments ranged from a high of $693.5 million in Q4 2024 and a low of $275.9 million during Q2 2025.
  • Its 3-year average for Long-Term Investments is $450.3 million, with a median of $384.3 million in 2023.
  • In the last 5 years, Royalty Pharma's Long-Term Investments spiked by 73.76% in 2024 and then slumped by 56.20% in 2025.
  • Royalty Pharma's Long-Term Investments (Quarterly) stood at $435.4 million in 2021, then fell by 8.78% to $397.2 million in 2022, then grew by 10.05% to $437.1 million in 2023, then skyrocketed by 58.66% to $693.5 million in 2024, then slumped by 53.98% to $302.5 million in 2025.
  • Its Long-Term Investments stands at $302.5 million for Q3 2025, versus $275.9 million for Q2 2025 and $336.2 million for Q1 2025.